Research programme: psoriasis foam therapies - Foamix/LEO Pharma

Drug Profile

Research programme: psoriasis foam therapies - Foamix/LEO Pharma

Alternative Names: Calcipotriol foam

Latest Information Update: 05 Jun 2013

Price : $50

At a glance

  • Originator Foamix; LEO Pharma
  • Class Antipsoriatics; Cyclohexanes; Dihydroxycholecalciferols; Indenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 05 Jun 2013 Discontinued - Preclinical for Psoriasis in Denmark (Topical)
  • 01 Dec 2005 Preclinical trials in Psoriasis in Denmark (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top